Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

There is a pressing need to capture and track subtle cognitive change at the preclinical
stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the
criteria for the neuropathological diagnosis of Alzheimer's disease. It is expected that Braak …

Advances in molecular positron emission tomography (PET) have enabled anatomic
tracking of brain pathology in longitudinal studies of normal aging and dementia, including …

Gut microbiota alterations might affect the development of Alzheimer's disease (AD) through
microbiota-derived metabolites. For example, microbiota-derived Indoles via tryptophan …

A panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau
pathologies in Alzheimer's disease (AD), although sensitive detection of frontotemporal …

Importance National Institute on Aging–Alzheimer's Association (NIA-AA) workgroups have
proposed biological research criteria intended to identify individuals with preclinical …

Introduction This study examines the utility of a multipanel of cerebrospinal fluid (CSF)
biomarkers complementing Alzheimer's disease (AD) biomarkers in a clinical research …